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Introduction
Pancreatic cancer is the third leading cause of cancer 
death in the United States, and estimates suggest it will 
become the second leading cause of cancer death by 2030 
due to an increased number of individuals older than 
age 65 as the baby boomer generation ages [1]. In 2017, 
over 53,000 new diagnoses of pancreatic cancer are expected 
in the United States, and projections expect over 43,000 
deaths will be attributed to pancreatic cancer this year 
[2]. Incidence rates for this cancer increased at a rate of 
1.2% per year between 2000 and 2012 and death rates 
increased by 0.4% [3]. Pancreatic cancer represents a 
particularly aggressive and lethal malignancy, with approxi-
mately 93% of pancreatic cancer patients dying within 
5 years of diagnosis [3, 4].
Pancreatic cancer is a disease of aging, occurring at 
increased rates in older adults, and these patients often 
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Abstract
Age, sex, and racial/ethnic disparities exist, but are understudied in pancreatic 
adenocarcinoma (PDAC). We used the Surveillance, Epidemiology, and End 
Results (SEER)–Medicare linked database to determine whether survival and 
treatment disparities persist after adjusting for demographic and clinical char-
acteristics. Our study included PDAC patients diagnosed between 1992 and 
2011. We used Cox regression to compare survival across age, sex, and race/
ethnicity within early- stage and late- stage cancer subgroups, adjusting for marital 
status, urban location, socioeconomics, SEER region, comorbidities, stage, lymph 
node status, tumor location, tumor grade, diagnosis year, and treatment received. 
We used logistic regression to compare differences in treatment received across 
age, sex, and race/ethnicity. Among 20,896 patients, 84% were White, 9% Black, 
5% Asian, and 2% Hispanic. Median age was 75; 56% were female and 53% 
had late- stage cancer. Among early- stage patients in the adjusted Cox model, 
older patient subgroups had worse survival compared with ages 66–69 (HR > 1.1, 
P < 0.01 for groups >69); no survival differences existed between sexes. Black 
(HR = 1.1, P = 0.01) and Hispanic (HR = 1.2, P < 0.01) patients had worse 
survival compared with White. Among late- stage cancer patients, patients over 
age 84 had worse survival than those aged 66–69 (HR = 1.1, P < 0.01), and 
males (HR = 1.08, P < 0.01) had worse survival than females; there were no 
racial/ethnic differences. Older age and minority race/ethnicity were associated 
with lower likelihood of receiving chemotherapy, radiation, and/or surgery. Age 
and racial/ethnic disparities in survival outcomes and treatment received exist 
for PDAC patients; these disparities persist after adjusting for differences in 
demographic and clinical characteristics.
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experience worse outcomes related to the disease [5–7]. 
Studies suggest that older patients are typically less likely 
to receive treatment for their pancreatic cancer and to 
have worse survival outcomes [8]. These poor results may 
be related to older patients’ complex geriatric issues, such 
as medical comorbidities, poor nutrition, impaired physical 
and cognitive function, and limited social support [9–13]. 
Thus, there is a critical need for further research to char-
acterize the impact of age on treatment received and 
survival outcomes in patients with pancreatic cancer in 
order to inform optimal management of the geriatric 
oncology population.
In addition, prior research suggests that patients’ sex 
and race/ethnicity may influence the treatment received 
and survival outcomes among patients with pancreatic 
cancer. In a study investigating the use and effectiveness 
of cancer- directed therapy among patients with locally 
advanced pancreatic cancer between 1991 and 1996, male 
patients appeared to be more likely to receive treatment 
compared with women, yet this finding did not persist 
after controlling for potential confounders, such as age, 
place of residence, and comorbidities [14]. Research 
studying racial/ethnic disparities in pancreatic cancer has 
demonstrated higher incidence rates in the Black popula-
tion compared with White, Hispanic, and Asian popula-
tions [15]. Death rates due to pancreatic cancer also 
appear to be worse in the Black population compared 
with White, Hispanic, and Asian populations [15]. 
Potential explanations for these survival differences 
include treatment disparities among different racial and 
socioeconomic populations [16]. Other explanations for 
survival differences among racial and ethnic groups 
include factors such as smoking, obesity [17], and tumor 
characteristics [18].
Although prior studies suggest the presence of age, sex, 
and racial/ethnic disparities regarding cancer outcomes, 
additional research is needed to investigate the relationship 
between these demographic factors and clinical factors 
such as cancer stage, comorbidity, and treatment received 
to better understand potential disparities in survival among 
patients with pancreatic cancer. We used the Surveillance, 
Epidemiology, and End Results (SEER)–Medicare linked 
database to study patients with pancreatic adenocarcinoma 
(PDAC) and further determine whether age, sex, or race/
ethnic differences in treatment received and/or survival 
outcomes exist after controlling for potential confounders 
such as patient sociodemographics and tumor character-
istics. We hypothesized that these potential confounding 
factors may only partially explain the differences in treat-
ment received and survival among these subgroups, thus 
highlighting the need for future research to identify addi-
tional factors to target in efforts to minimize disparities 
in pancreatic cancer outcomes.
Methods
Cohort inclusion/exclusion criteria
We used data from the 2015 release of the SEER–Medicare 
database to estimate differences in treatment received and 
survival among patients with PDAC based on age, sex, 
and race/ethnicity. The SEER database comprises approxi-
mately 28% of the U.S. population and includes informa-
tion about tumor characteristics, incidence, and survival. 
The Medicare database includes claims information for 
approximately 97% of Medicare patients aged 65 or older 
[19]. The SEER–Medicare database links SEER registry data 
to Medicare enrollment and claims files, including Parts 
A and B claims for covered health care services, and can 
be used to examine patterns of care among cancer patients.
Patients were included if they were diagnosed at 65+ 
and had a microscopically confirmed (histology or cytol-
ogy) PDAC diagnosed between 1 January 1992 and 31 
December 2011. Adenocarcinoma histology was based on 
the International Classification of Diseases for Oncology 
(ICD- O- 3) codes listed in Table S1. Only patients with 
PDAC as their primary cancer and continuous enrollment 
in Medicare Parts A and B from 13 months prior to 
their diagnosis to death or 31 December 2013 were included 
in our analysis. To ensure that we completely captured 
claims data regarding heath care services, we excluded 
patients enrolled in an HMO during this period because 
no billing information regarding HMO services is available 
in this database. Stage is based on the derived SEER stage 
variable for the sixth edition of the AJCC Cancer Staging 
Manual; those prior to 2004 were classified by mapping 
the SEER variables for extension of disease and lymph 
node involvement to the appropriate AJCC sixth edition 
stage. Patients in which we could not determine AJCC 
stage were excluded. The N classification variable was 
based on lymph node involvement (N0, no lymph nodes; 
N1 at least one node; unknown, node involvement not 
known). We imputed socioeconomic status by using U.S. 
Census data provided in SEER–Medicare to derive quintiles 
of ZIP code- level median household income. We catego-
rized patients into four race/ethnicity groups (White, Black, 
Hispanic, Asian) using SEER variables; 62 patients coded 
as Native American and 58 patients coded as unknown 
race/ethnicity were excluded. The final cohort was 20,896 
patients: 9773 (46.8%) were early stage (I–III) and 11,123 
(53.2%) were late stage (stage IV). A flowchart showing 
how the final cohort was derived is showed in Figure S1.
Statistical analysis
We compared the distribution of all patient and cancer 
characteristics included in the analysis across age, sex, 
and race/ethnic groups using a chi- square test. We divided 
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patients into two cohorts (early stage [I–III] and late stage 
[IV]) to examine survival differences across age, sex, and 
race/ethnicity among early- stage and late- stage patients 
independently. We chose to analyze stage IV separately 
due to the difference in treatment patterns found in this 
stage group; metastatic patients are generally offered non-
surgical treatment. We used Kaplan–Meier to estimate 
survival within subgroups of age, sex, and race/ethnicity, 
with patients alive on 31 December 2013 censored, and 
potential differences assessed using the log- rank test.
We classified patients as having received surgery, radia-
tion, and/or chemotherapy if they had at least one Medicare 
claim after diagnosis, based on codes listed in Table S1. 
We calculated comorbidity scores using the Deyo adapta-
tion of the Charlson comorbidity index to Medicare inpa-
tient, outpatient, and physician claims during the 13- month 
period prior to cancer diagnosis [20–22]. We classified 
the scores into three groups (0, 1, and 2+).
We examined whether age, sex, and race/ethnic differ-
ences were predictors of treatment receipt (surgery, radia-
tion, or chemotherapy) after controlling for other 
demographic and clinical predictors using logistic regression 
models. To examine whether age, sex, and race/ethnic 
differences in overall survival remained after controlling 
for other demographic and clinical predictors, we used 
Cox proportional hazard models in both the early- stage 
and late- stage patient cohorts to compare hazard ratios. 
We included the following variables in the models: age 
at diagnosis; sex; race/ethnicity; marital status; urban/rural 
location; SES (census tract quintile); SEER region, year 
of diagnosis, AJCC stage, comorbidity score; receipt of 
surgery, radiation, or chemotherapy; tumor location (pan-
creatic head, body/tail, or other); N stage (N0, N1, or 
unknown); and tumor grade (low, intermediate, poor/
undifferentiated, or unknown). To assess for interactions 
between stage (I–III vs. IV) and age, sex, and race/ethnic-
ity, we used Cox proportional hazard models to test for 
an interaction effect between each of these covariates.
We defined statistical significance as P < 0.05 in a 
two- sided test. We performed statistical analysis using SAS 
software, version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Demographics and clinical characteristics
In our cohort of 20,896, there were 3906 (19%) patients 
aged 66–69, 5688 (27%) aged 70–74, 5508 (26%) aged 
75–79, 3732 (18%) aged 80–84, and 2062 (10%) aged 85 
or older. There were 11,599 (56%) female patients and 
9297 (44%) males. Most patients were White (n = 17,541; 
84%), and fewer were Black (n = 1889; 9%), Asian 
(n = 1062; 5%), and Hispanic (n = 404; 2%). Patients 
over age 65 who were excluded (N = 30,806) were more 
likely to be male (47% vs. 44%, P < 0.0001), a race/
ethnicity other than White (22% vs. 16%, P < 0.0001), 
or diagnosed in the older age subgroup (85+ years old; 
12% vs. 10%, P < 0.0001). The complete list of demo-
graphics and clinical characteristics for the final cohort 
are found in Tables 1 and 2, respectively.
Patients in the 66–69 and 70–74 age groups were more 
likely to be married, have a lower comorbidity score, and 
to be diagnosed with late- stage disease. Male patients were 
more likely to have a younger diagnosis age, to be mar-
ried, and they had a higher comorbidity score than female 
patients. Black and Hispanic patients were less likely to 
be married, and they had a lower SES, were diagnosed 
at a younger age, and had a higher Charlson comorbidity 
score compared with the Asian and White populations. 
Black patients were also more likely to have late- stage 
PDAC.
Treatment factors
Rates of surgery receipt among the entire cohort increased 
over time, with 8.9% of patients diagnosed in 1992–1993 
receiving surgery and 17.8% diagnosed in 2009–2011 
receiving surgery (Fig. 1). Chemotherapy rates also steadily 
increased, with 32.5% of patients diagnosed in 1992–1993 
receiving chemotherapy and 58.5% diagnosed in 2009–2011 
receiving chemotherapy. Rates of radiation receipt gener-
ally remained stable over time, with 21.7% of patients 
diagnosed in 1992–1993 receiving radiation and 23.6% 
diagnosed in 2009–2011 receiving radiation.
Younger patient subgroups (those aged 66–80) were 
more likely to have received surgery, radiation, or chemo-
therapy than the older subgroups, and male patients were 
more likely to have received radiation or chemotherapy 
than female patients. Black patients were least likely to 
have received surgery, radiation, or chemotherapy com-
pared to the other racial subgroups. Using logistic regres-
sion models, we sought to determine whether the differences 
in treatment received were significant after adjusting for 
other baseline sociodemographic and cancer characteristics 
(full logistic regression modeling results listed in Table 
S2). For surgery, age (P < 0.0001) and race/ethnicity 
(P = 0.0002) and were both significant predictors, while 
sex was not (P = 0.41). These results were consistent for 
the radiation (age: P < 0.0001; sex: P = 0.56; race/ethnic-
ity: P = 0.001) and chemotherapy (age: P < 0.0001; sex: 
P = 0.30; race/ethnicity: P = 0.0001) models. Among 
early- stage patients, age and race/ethnicity were both sig-
nificant predictors for surgery (P < 0.0001 and P = 0.02, 
respectively) and chemotherapy (P < 0.0001 and P = 0.004, 
respectively). Only age (P < 0.0001) was a significant 
predictor of receipt of radiation. Sex was not significant 
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for any of the treatment models. Among late- stage patients, 
none of the three variables were significant predictors of 
surgery, while only age (P < 0.0001) was a significant 
predictor of chemotherapy. Age and race/ethnicity were 
both significant predictors for radiation (P < 0.0001 and 
P = 0.005, respectively), while sex was not significant.
Survival outcomes
In the univariate Cox proportional hazards model using 
the interaction terms for stage age, sex, and race/ethnicity, 
we found significant effects between stage and sex 
(P = 0.005) and stage and race/ethnicity (P = 0.0008); 
however, there was no effect between stage and age 
(P = 0.68). We examined survival outcomes between 
early- stage and late- stage patients separately in both the 
Kaplan–Meier survival curves and adjusted models. 
Figure 2 shows the Kaplan–Meier survival curve for early- 
stage patients stratified by age, sex, and race/ethnicity. 
The median overall survival for this cohort was 8.7 months. 
The median survival decreased among age groups, from 
11.2 months for ages 66–69 to 4.8 months for ages 85+. 
The median survival for males and females was 8.9 and 
8.6 months, respectively. Survival was worse for Black 
(6.6 months) and Hispanic (6.6 months) then for White 
(9.0 months) and Asian (8.7 months) patients. At 3 years, 
the survival rates for early- stage patients were 9.9%, 6.4%, 
6.5%, and 10.3% for White, Black, Hispanic, and Asian 
patients, respectively (survival rates are shown in Table 
S3).
Figure 3 displays the Kaplan–Meier survival curves for 
late- stage patients stratified by age, sex, and race/ethnicity. 
The median overall survival for this cohort was 2.9 months. 
The median survival decreased among age groups, from 
5.9 months for ages 66–69 to 3.3 months for ages 85+. 
The median survival for males and females was 2.8 and 
2.9 months, respectively. Survival was worse for Black 
(2.6 months) and Hispanic (2.6 months) than for White 
(2.9 months) and Asian (3.3 months) patients. For late- 
stage patients, the 2- year survival rates were 1.9%, 1.1%, 
0.9%, and 3.0% for White, Black, Hispanic, and Asian 
patients, respectively (survival rates are shown in Table 
S3).
Adjustment effects
We ran separate Cox proportional hazards models on the 
early- stage (I–III) and late- stage (IV) patients (full models 
shown in Table S4). Older patients had worse survival 
when compared to patients aged 66–69 (HR: 1.1 and 
above for all age groups, P < 0.01 for all) in both the 
unadjusted and adjusted models, but we found no survival 
differences between sexes (Table 3). In the unadjusted 
model of early- stage cancer patients, Black (HR 1.27, 
P < 0.0001) and Hispanic (HR 1.26, P = 0.002) patients 
had worse survival when compared to White patients. 
These survival differences persisted after adjustment for 
patient and tumor characteristics (Black [HR 1.11, 
P = 0.01] and Hispanic [HR 1.24, P = 0.005]). Asian 
patients had no survival differences when compared to 
White patients in both the unadjusted (HR 1.06, P = 0.24) 
and adjusted (HR 1.06, P = 0.26) models.
Among late- stage cancer patients, the oldest patient age 
group had worse survival when compared to younger 
patients (HR: 1.1 for age 85+ compared to 66–69 years, 
P < 0.01), and males (HR: 1.08, P < 0.01) had worse 
survival than females. Black and Hispanic patients had no 
survival difference compared with White patients (Table 3).
Figure 1. Treatment of stage I–IV pancreatic adenocarcinoma patients by year of diagnosis.
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Discussion
Our study demonstrates disparities for treatment received 
and survival across age, sex, and race/ethnicity among 
patients with pancreatic cancer. We found that older patients 
and Black and Hispanic patients with early- stage pancreatic 
cancer experience worse survival outcomes compared to 
their counterparts even after adjusting for potential con-
founding sociodemographic and clinical factors. We also 
found that various clinical factors such as comorbidities 
and treatment do not appear to fully explain the survival 
differences among the age and race/ethnic subgroups. Among 
patients with late- stage disease, the survival differences across 
age and race/ethnicity were largely insignificant after adjust-
ment. This is potentially due to the fact that these patients 
tend to present at a very late stage in their disease, with 
short survival times. Notably, our findings suggest similar 
outcomes for male and female patients in early- stage disease, 
although males had slightly worse survival than females in 
the adjusted model of late- stage pancreatic cancer. 
Collectively, these findings suggest that disparities persist 
for patients with pancreatic cancer across age, sex, and 
race/ethnicity, yet ongoing research is needed to further 
determine the etiology of these disparities.
Our findings align with several previous studies dem-
onstrating survival differences based on patient age and 
race/ethnicity [16, 23, 24]. For example, Amin (2012) 
demonstrated that both treatment prevalence and survival 
decreased as age increased, despite any recent advances 
in these regimens [8]. Singal et al. showed that Black 
patients experience worse survival than White patients, 
even after controlling for patient and tumor characteristics, 
yet there were no survival differences between White 
patients and the Asian or Hispanic population [16]. Other 
studies have shown mixed results regarding outcomes in 
the Hispanic patient population. Research by Jou et al. 
demonstrated similar overall survival among Hispanic and 
Black patients when compared to White patients treated 
in a New York City cancer center, while Bathe et al. 
showed that Hispanic patients had worse outcomes com-
pare to White patients after tumor resection in the pancreas 
head [25, 26].
Our research further adds to this work by providing 
an updated analysis that included additional important 
variables. Many of these studies used SEER without link-
age to Medicare data, which does not include important 
treatment factors such as receipt of chemotherapy, and 
individual patient factors such as medical comorbidities. 
Figure 2. Kaplan–Meier survival curve for early- stage (I–III) pancreatic adenocarcinoma patients (A) race, (B) age, and (C) sex.
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The use of a linked SEER–Medicare database allowed us 
to adjust for these vital factors unavailable in SEER, includ-
ing comorbidities, chemotherapy use, and socioeconomic 
status based on zip code and median income. In addition, 
our study includes more recent SEER data, which may 
be significant as treatments for pancreatic cancer have 
rapidly evolved in more recent years. Importantly, our 
findings suggest that even after including this additional 
factors, such as chemotherapy, comorbidities, and other 
tumor characteristics, disparities in receipt of treatment 
do not fully explain the disparities in survival differences 
across age, sex, and race/ethnicity.
The persistence of these disparities suggests the exist-
ence of additional unmeasured factors that we could not 
control for. In addition, biases and interactions that we 
could not control for may also play a role in the dispari-
ties we demonstrated. For example, differences in tumor 
biology by both age and race/ethnicity may be an impor-
tant factor, which needs to be studied in future research. 
Prior work on other cancers, such as ovarian and prostate, 
suggests that malignancies detected at an older age are 
more aggressive, but this needs to be studied within pan-
creatic cancer [27–29]. Similarly, heterogeneity in tumor 
indolence/invasiveness has been reported by race/ethnicity 
for various cancers, such as a 2006 study by Lee et al. 
demonstrating that Black patients present with bladder 
cancer at a higher stage and tumor grade [30–32]. Research 
by Powell et al. suggests that prostate cancer grows more 
rapidly and becomes more aggressive among Black men 
when compared to White. These potential differences in 
other cancers highlight the need for further research in 
this area in pancreatic cancer patients.
Our study is subject to several limitations inherent to 
administrative data. Since SEER–Medicare only includes 
patients 65 years or older and we excluded 65- year- old 
patients to allow us to calculate comorbidity scores in 
the year prior to diagnosis, we were unable to conduct 
analyses on younger patient populations. However, pan-
creatic cancer is more common among older age groups, 
with approximately 66% of patients aged 65 or older 
[33]. Other factors that could explain the poorer survival 
outcomes across age, sex, and race/ethnicity, such as smok-
ing history, family history, and obesity are not completely 
reported in the SEER–Medicare database. For example, 
BMI category claim codes were recorded for only approxi-
mately 200 patients out of our cohort of 20,896. A previ-
ous study by Arnold et al. [17] demonstrated that factors 
such as smoking and obesity play a major role in pancreatic 
Figure 3. Kaplan–Meier survival curve for late- stage (IV) pancreatic adenocarcinoma patients (A) race, (B) age, and (C) sex.
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cancer risk, with obesity playing a significant role in risk 
among White men and women, and among Black men, 
although this study could not show whether these con-
tributed to the outcome disparities seen among racial 
groups. Further research into genetic and other factors 
is needed, with the goal of helping to better explain these 
disparities.
In summary, age, sex, and racial disparities in survival 
outcomes and treatment received exist for patients with 
pancreatic cancer. These disparities persist after adjusting 
for differences in sociodemographic, clinical, and treat-
ment characteristics. Future research into other potential 
factors that can help further explain these findings is 
warranted.
Conflicts of Interest
There are no conflicts of interest to disclose.
References
 1. Rahib, L., B. D. Smith, R. Aizenberg, A. B. Rosenzweig, 
J. M. Fleshman, and L. M. Matrisian. 2014. Projecting 
cancer incidence and deaths to 2030: the unexpected 
burden of thyroid, liver, and pancreas cancers in the 
United States. Cancer Res. 74:2913–2921.
 2. Siegel, R. L., K. D. Miller, and A. Jemal. 2017. Cancer 
statistics, 2017. CA Cancer J. Clin. 67:7–30.
 3. American Cancer Society. 2016. Cancer facts & figures 
2016. American Cancer Society, Atlanta, GA.
 4. Jemal, A., R. Siegel, J. Xu, and E. Ward. 2010. Cancer 
statistics, 2010. CA Cancer J. Clin. 60:277–300.
 5. Siegel, R. L., K. D. Miller, and A. Jemal. 2015. Cancer 
statistics, 2015. CA Cancer J. Clin. 65:5–29.
 6. Yancik, R. 2005. Population aging and cancer: a 
cross- national concern. Cancer J. 11:437–441.
 7. Enzinger, P. C., and R. J. Mayer. 2004. Gastrointestinal 
cancer in older patients. Semin. Oncol. 31:206–219.
Table 3. Cox proportional hazard ratios for overall survival, adjusted for patient characteristics.
Unadjusted models Adjusted model1,2
HR 95% CI P HR 95% CI P
Early stage (I–III) cohort
Race/ethnicity
White (ref) 1 1
Black 1.27 1.18–1.37 <0.0001 1.11 1.02–1.20 0.01
Hispanic 1.26 1.09–1.46 0.002 1.24 1.07–1.43 0.005
Asian 1.06 0.97–1.16 0.24 1.06 0.96–1.15 0.26
Age
66–69 (ref) 1 1
70–74 1.11 1.04–1.18 0.0009 1.10 1.02–1.16 0.003
75–79 1.23 1.16–1.31 <0.0001 1.12 1.05–1.19 0.0004
80–84 1.44 1.35–1.54 <0.0001 1.19 1.11–1.28 <0.0001
85+ 2.00 1.85–2.17 <0.0001 1.37 1.26–1.49 <0.0001
Sex
Female (ref) 1 1
Male 0.97 0.93–1.01 0.19 1.04 0.99–1.08 0.12
Late stage (IV) cohort
Race/ethnicity
White (ref) 1 1
Black 1.13 1.06–1.20 0.0002 0.997 0.93–1.07 0.94
Hispanic 1.09 0.95–1.25 0.22 1.03 0.90–1.19 0.65
Asian 0.89 0.81–0.97 0.009 0.82 0.75–0.90 <0.0001
Age
66–69 (ref) 1 1
70–74 1.07 1.02–1.14 0.01 1.05 0.999–1.11 0.07
75–79 1.16 1.10–1.23 <0.0001 1.05 0.99–1.11 0.10
80–84 1.34 1.26–1.43 <0.0001 1.06 0.994–1.13 0.08
85+ 1.73 1.60–1.86 <0.0001 1.14 1.06–1.24 0.0006
Sex
Female (ref) 1 1
Male 1.03 0.99–1.07 0.14 1.08 1.04–1.13 <0.0001
1Variables included in the adjusted model: AJCC cancer stage, N stage, Charlson comorbidity score, year of diagnosis, SEER region, SES, tumor 
 location, surgery, radiation, chemotherapy, tumor grade, marital status, urban location.
2Variables included in the adjusted model: race/ethnicity, age at diagnosis, sex, Charlson comorbidity score, year of diagnosis, SEER region, SES, tumor 
location, surgery, radiation, chemotherapy, tumor grade, marital status, urban location.
534 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
R. Nipp et al.Pancreatic Cancer Outcome Disparities
 8. Amin, S., A. L. Lucas, and H. Frucht. 2013. Evidence 
for treatment and survival disparities by age in 
pancreatic adenocarcinoma: a population- based analysis. 
Pancreas 42:249–253.
 9. Barbas, A. S., R. S. Turley, E. P. Ceppa, S. K. Reddy, 
D. G. Blazer, B. M. Clary, et al. 2012. Comparison of 
outcomes and the use of multimodality therapy in 
young and elderly people undergoing surgical resection 
of pancreatic cancer. J. Am. Geriatr. Soc. 60:344–350.
10. Dale, W., J. Hemmerich, A. Kamm, M. C. Posner, J. B. 
Matthews, R. Rothman, et al. 2014. Geriatric assessment 
improves prediction of surgical outcomes in older adults 
undergoing pancreaticoduodenectomy: a prospective 
cohort study. Ann. Surg. 259:960–965.
11. Dias-Santos, D., C. R. Ferrone, H. Zheng, K. D. 
Lillemoe, and C. Fernandez-Del Castillo. 2015. The 
Charlson age comorbidity index predicts early mortality 
after surgery for pancreatic cancer. Surgery 157:881–887.
12. Nipp, R. D., A. Zanconato, H. Zheng, C. R. Ferrone, 
K. D. Lillemoe, J. Y. Wo, et al. 2017. Predictors of 
early mortality after surgical resection of pancreatic 
adenocarcinoma in the era of neoadjuvant treatment. 
Pancreas 46:183–189.
13. Bilimoria, K. Y., D. J. Bentrem, C. Y. Ko, A. K. 
Stewart, D. P. Winchester, and M. S. Talamonti. 2007. 
National failure to operate on early stage pancreatic 
cancer. Ann. Surg. 246:173–180.
14. Krzyzanowska, M. K., J. C. Weeks, and C. C. Earle. 
2003. Treatment of locally advanced pancreatic cancer 
in the real world: population- based practices and 
effectiveness. J. Clin. Oncol. 21:3409–3414.
15. Howlader, N., A. Noone, M. Krapcho, D. Miller, K. 
Bishop, S. F. Altekruse, et al. SEER cancer statistics 
review, 1975–2013. National Cancer Institute, Bethesda, 
MD.
16. Singal, V., A. K. Singal, and Y. F. Kuo. 2012. Racial 
disparities in treatment for pancreatic cancer and impact 
on survival: a population- based analysis. J. Cancer Res. 
Clin. Oncol. 138:715–722.
17. Arnold, L. D., A. V. Patel, Y. Yan, E. J. Jacobs, M. J. 
Thun, E. E. Calle, et al. 2009. Are racial disparities in 
pancreatic cancer explained by smoking and overweight/
obesity? Cancer Epidemiol. Biomarkers Prev. 
18:2397–2405.
18. Shavers, V. L., L. C. Harlan, M. Jackson, and J. 
Robinson. 2009. Racial/ethnic patterns of care for 
pancreatic cancer. J. Palliat. Med. 12:623–630.
19. Warren, J. L., C. N. Klabunde, D. Schrag, P. B. Bach, 
and G. F. Riley. 2002. Overview of the SEER- Medicare 
data: content, research applications, and generalizability 
to the United States elderly population. Med. Care. 
40:IV-3–IV-18.
20. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. 
MacKenzie. 1987. A new method of classifying 
prognostic comorbidity in longitudinal studies: 
development and validation. J. Chronic Dis. 40:373–383.
21. Deyo, R. A., D. C. Cherkin, and M. A. Ciol. 1992. 
Adapting a clinical comorbidity index for use with 
ICD- 9- CM administrative databases. J. Clin. Epidemiol. 
45:613–619.
22. Romano, P. S., L. L. Roos, and J. G. Jollis. 1993. 
Adapting a clinical comorbidity index for use with 
ICD- 9- CM administrative data: differing perspectives. J. 
Clin. Epidemiol. 46:1075–1079.
23. Murphy, M. M., J. P. Simons, J. S. Hill, T. P. McDade, 
S. Chau Ng, G. F. Whalen, et al. 2009. Pancreatic 
resection: a key component to reducing racial 
disparities in pancreatic adenocarcinoma. Cancer 
115:3979–3990.
24. Riall, T. S., C. M. Jr Townsend, Y. F. Kuo, J. L. 
Freeman, and J. S. Goodwin. 2010. Dissecting racial 
disparities in the treatment of patients with 
locoregional pancreatic cancer: a 2- step process. 
Cancer 116:930–939.
25. Bathe, O. F., H. Caldera, K. Hamilton-Nelson, D. 
Franceschi, D. Sleeman, J. U. Levi, et al. 2001. Influence 
of Hispanic ethnicity on outcome after resection of 
carcinoma of the head of the pancreas. Cancer 
91:1177–1184.
26. Jou, E., M. Shusterman, J. W. Chuy, A. Kaubisch, S. 
Aparo, and S. Goel. 2016. Analysis of survival outcomes 
among ethnic minorities with pancreatic cancer treated 
at an urban academic cancer center. J. Clin. Oncol. 
34(suppl):e15734.
27. Poole, E. M., M. A. Merritt, S. J. Jordan, H. P. Yang, 
S. E. Hankinson, Y. Park, et al. 2013. Hormonal and 
reproductive risk factors for epithelial ovarian cancer by 
tumor aggressiveness. Cancer Epidemiol. Biomarkers 
Prev. 22:429–437.
28. Vellekoop, A., and S. Loeb. 2013. More aggressive 
prostate cancer in elderly men. Rev. Urol. 15: 
202–204.
29. Weigel, S., H. W. Hense, J. Heidrich, S. Berkemeyer, 
W. Heindel, and O. Heidinger. 2016. Digital 
mammography screening: does age influence the 
detection rates of low- , intermediate- , and high- 
grade ductal carcinoma in situ? Radiology 278: 
707–713.
30. Powell, I. J., C. H. Bock, J. J. Ruterbusch, and W. Sakr. 
2010. Evidence supports a faster growth rate and/or 
earlier transformation to clinically significant prostate 
cancer in black than in white American men, and 
influences racial progression and mortality disparity. J. 
Urol. 183:1792–1796.
31. Lee, C. T., R. L. Dunn, C. Williams, W. Underwood 
3rd. 2006. Racial disparity in bladder cancer: trends in 
tumor presentation at diagnosis. J. Urol. 176:927–933; 
discussions 933–924.
535© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Pancreatic Cancer Outcome DisparitiesR. Nipp et al.
32. Keenan, T., B. Moy, E. A. Mroz, K. Ross, A. 
Niemierko, J. W. Rocco, et al. 2015. Comparison of the 
genomic landscape between primary breast cancer in 
African American versus white women and the 
association of racial differences with tumor recurrence. 
J. Clin. Oncol. 33:3621–3627.
33. Surveillance Research Program. Fast Stats (Pancreas 
Cancer): An interactive tool for access to SEER cancer 
statistics. Surveillance Research Program, National 
Cancer Institute, http://seer.cancer.gov/statfacts/html/
pancreas.html (accessed 21 December 2016).
Supporting Information
Additional supporting information may be found in the 
online version of this article:
Table S1. Medicare billing and SEER codes.
Figure S1. Flowchart of inclusion/exclusion criteria.
Table S2. Factors associated with receipt of treatment.
Table S3. Kaplan–Meier overall survival rate estimates.
Table S4. Cox proportional hazard ratios for overall sur-
vival, adjusted for patient characteristics.
